HC Wainwright Weighs in on Traws Pharma FY2030 Earnings

Traws Pharma, Inc. (NASDAQ:TRAW) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Traws Pharma in a note issued to investors on Wednesday, May 20th. HC Wainwright analyst B. Folkes forecasts that the company will earn $0.52 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($2.72) per share.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.39.

Other research analysts have also recently issued reports about the company. LADENBURG THALM/SH SH upgraded Traws Pharma to a “strong-buy” rating in a report on Friday, January 30th. Weiss Ratings cut Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Traws Pharma has an average rating of “Moderate Buy” and an average target price of $8.00.

Traws Pharma Stock Performance

TRAW opened at $1.62 on Thursday. Traws Pharma has a one year low of $1.00 and a one year high of $3.27. The stock has a market capitalization of $16.46 million, a PE ratio of -0.96 and a beta of 1.47. The business’s 50 day moving average price is $1.68 and its 200 day moving average price is $1.83.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP acquired a new position in Traws Pharma during the fourth quarter worth $56,000. XTX Topco Ltd lifted its stake in Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after purchasing an additional 31,502 shares in the last quarter. Ikarian Capital LLC lifted its stake in Traws Pharma by 2,280.0% during the fourth quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after purchasing an additional 649,649 shares in the last quarter. Squadron Capital Management LLC acquired a new position in Traws Pharma during the fourth quarter worth $806,000. Finally, Boothbay Fund Management LLC acquired a new position in Traws Pharma during the fourth quarter worth $220,000. 7.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were bought at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the purchase, the insider directly owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 14.00% of the stock is owned by company insiders.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.